- Home
- MMLP vs LITS Comparison
MMLP vs LITS Comparison
Compare MMLP & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMLP | LITS |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 42.2M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | MMLP | LITS |
|---|---|---|
| Price | $2.83 | $1.13 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 15.9K | ★ 287.2K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $2.21 | $0.95 |
| 52 Week High | $3.58 | $3.03 |
Technical Indicators
Market Signals| Indicator | MMLP | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 47.11 |
| Support Level | $2.56 | $0.98 |
| Resistance Level | $3.01 | $1.16 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 74.63 | 39.13 |
Price Performance
Historical ComparisonAbout MMLP Martin Midstream Partners L.P. Limited Partnership
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.